
    
      Patients who wish to participate in the extension study must provide written Informed
      Consent. Treatment will begin after completion of the End of Study (EOS) or End of Treatment
      (EOT) visit of the Original Study. The assessments obtained at the EOS or EOT visit will
      serve as Baseline data for the extension study.

      Patients will continue to receive poziotinib treatment at the last dose received or at the
      standard starting dose of 16 milligrams (mg) poziotinib, once daily.

      Patients may receive treatment as long as the patient is deriving clinical benefit, as judged
      by the investigator or treating physician (case-by-case decision with approval of Spectrum),
      death, withdrawal of consent, unacceptable toxicity, lost to follow-up, or poziotinib
      receives commercial approval in their country of residence or development is terminated by
      the Sponsor, whichever occurs first. There will be an EOS Visit 35 (Â±5) days after the last
      dose of poziotinib.
    
  